LOXO ONCOLOGY,INC. (NASDAQ:LOXO) Files An 8-K Regulation FD Disclosure

ME Staff 8-k
-
0
LOXO ONCOLOGY,INC. (NASDAQ:LOXO) Files An 8-K Regulation FD Disclosure

LOXO ONCOLOGY,INC. (NASDAQ:LOXO) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD.

On December6, 2018, Loxo Oncology,Inc. (“Loxo Oncology”), received its first milestone payment to its collaboration with Bayer, equal to $275 million, which was earned upon the grant of U.S. Food and Drug Administration marketing approval for Vitrakvi® (larotrectinib).

The information furnished with this report shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.


About LOXO ONCOLOGY,INC. (NASDAQ:LOXO)

Loxo Oncology, Inc. is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer. Its pipeline includes LOXO-101, LOXO-195, Rearranged During Transfection (RET) Program and Fibroblast Growth Factor Receptor (FGFR) program. LOXO-101 is a selective inhibitor of tropomyosin receptor kinases (TRK) for the treatment of patients with soft tissue sarcoma. LOXO-195 is a selective TRK inhibitor capable of addressing potential mechanisms of acquired resistance that may emerge in patients receiving LOXO-101 or multikinase inhibitors with anti-TRK activity. It has designed a series of RET inhibitors that optimize on-target potency for RET gene fusions, mutations and clinically-identified resistance mutations. It is designing FGFR1-sparing FGFR inhibitor.